The article reports on a large study presented at the European Society of Cardiology Congress, which found that initiating statin therapy shortly after a type 2 diabetes diagnosis may be associated with a reduced risk of dementia. The study, published in The Lancet Regional Health – Europe, analyzed health data from 132,585 Danish patients diagnosed with type 2 diabetes between 2006 and 2019, who had no prior history of statin use or dementia. The research indicated that adults who began taking a statin within one year of their diabetes diagnosis had a 15% lower relative risk of developing dementia over 10 years compared to those who did not start the medication within five years. Even for individuals who initiated statin therapy one to five years after diagnosis, there was still a 10% lower relative risk of dementia.

Dr. Liron Sinvani, a geriatrician and director for research and innovation at the Northwell Institute for Healthy Aging, characterized the study as a “well-designed, large-scale observational study” that contributes to the growing evidence suggesting statins may protect brain health. She emphasized that while the 15% reduction in dementia risk is modest, it remains “very significant.” The study’s findings align with previous research indicating that people with type 2 diabetes have an increased risk of cognitive decline and heart disease. Although guidelines generally recommend statins for many adults aged 40 to 75 with diabetes, statin treatment is not always initiated promptly after a type 2 diabetes diagnosis. The article notes the study’s limitations, including its observational nature, which precludes definitive conclusions about a causal relationship between statins and reduced dementia risk. Source

This is a summary. Read the original at health.yahoo.com.